Replimune Group, Inc. (REPL) Covered Calls

You can sell covered calls on Replimune Group, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for REPL (prices last updated Fri 4:16 PM ET):

Replimune Group, Inc. (REPL) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
13.98 -0.33 13.48 14.75 640K - 1.1
Covered Calls For Replimune Group, Inc. (REPL)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 21 15 0.45 14.30 3.1% 39.0%
Apr 17 15 0.60 14.15 4.2% 27.4%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.